Optimizing the Approval Pathway for Biosimilars to Treat Psoriasis and Psoriatic Arthritis [PDF]
, 2012 Sheila Rittenberg, Bethany Wofford
openalex +1 more source
Matching-adjusted indirect comparison of tislelizumab plus lenvatinib versus sintilimab plus bevacizumab biosimilar as first-line treatment for unresectable hepatocellular carcinoma. [PDF]
Front ImmunolWang K, Liu C, Song X, Zhao N, Zheng X.
europepmc +1 more source
A European perspective on the market accessibility of biosimilars
, 2012 Paul Declerck, Steven Simoens
openalex +2 more sources
Demand- Versus Supply-Side Policies in Market Penetration of Biosimilars: Which is More Effective? [PDF]
BioDrugsShin G, Han H, Choi G, Lee D, Bae S.
europepmc +1 more source
Medicare spending and use of subcutaneous biologic formulations with hyaluronidase. [PDF]
OncologistKim J +3 more
europepmc +1 more source
Is Extrapolation of the Safety and Efficacy Data in One Indication to Another Appropriate for Biosimilars? [PDF]
, 2013 Howard Lee
openalex +1 more source
Budget Impact Analysis of Biosimilar Infliximab Treatment for Rheumatoid Arthritis in Six Central European Countries [PDF]
, 2013 Valentin Brodszky +5 more
openalex +1 more source
Insulin Glargine Biosimilar Prescribing and Cost Trends in the United Kingdom's Primary Care from 2020 to 2024. [PDF]
Pharmacy (Basel)Alsaif M, Blumer Z.
europepmc +1 more source
Introduction of an Infliximab Biosimilar (CT-P13): A Five-Year Budget Impact Analysis for the Treatment of Rheumatoid Arthritis in Ireland [PDF]
, 2013 Géraldine McCarthy +2 more
openalex +1 more source
Switching from Adalimumab Reference Product to and Among Adalimumab Biosimilars Outside the USA: Insights for US Clinicians. [PDF]
BioDrugsTesser JRP, Charabaty A, Hebert AA.
europepmc +1 more source